An ongoing dialogue on HIV/AIDS, infectious diseases,
October 29th, 2011
Will An Antiretroviral Patch Help Adherence? Doubtful …
This little nugget came up recently, found by our Journal Watch Executive Editor:
Preliminary research suggests that a patch could deliver an AIDS drug to patients … The researchers successfully used transdermal patches to administer 96 percent of an AIDS drug to simulated skin over a week. “Still, the important limitation of pills, regardless of how few there are or even how minimal the side effects, is adherence,” Johnston [the investigator] noted. Research has shown that many patients, if not most, don’t take their pills all the time.
Setting aside for a moment the fact that most patients actually do take their medications just fine, thank you — and that this particular transdermal HIV drug delivery system hasn’t even been tested on animals, let alone humans — I have always wondered about the assumption that novel drug delivery systems would improve adherence.
Seems to me that the major problem with non-adherent patients isn’t that they can’t take pills.
It’s that they won’t take them.
And I strongly suspect that most would make the same choice when it comes to putting on a patch every day (or even every week).
2 Responses to “Will An Antiretroviral Patch Help Adherence? Doubtful …”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- A Regional Measles Outbreak — South Carolina, 2025–2026 August 13, 2026In South Carolina, 997 measles cases occurred in the reported outbreak. In one health care system, 81 cases were identified. Most were in unvaccinated persons; 13 persons were hospitalized, and 2 had measles encephalitis.
- iEvac-Z, an Inactivated Ebola Vaccine — Phase 1 Study in Japan August 13, 2026Ebola virus continues to be a global threat. In a phase 1 study, an inactivated Ebola virus vaccine was tested in healthy volunteers for safety and immunogenicity.
- Long-Acting Treatment and Advanced HIV Disease — Addressing a Public Health Priority August 13, 2026Without deliberate efforts to evaluate long-acting injectable ART in the populations that need these therapies most, their benefits may accrue primarily to people who are well served by existing systems.
- Disseminated Fusariosis August 13, 2026A 61-year-old man with prolonged neutropenia after chemotherapy for AML was evaluated for persistent fever despite antimicrobial therapy. Physical examination was notable for a skin macule with central necrosis on the chest.
- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 August 6, 2026Bundibugyo virus, a filovirus, is currently spreading in the Democratic Republic of Congo. This report presents early data on symptoms and illness severity as well as diagnostic challenges.
- A Regional Measles Outbreak — South Carolina, 2025–2026 August 13, 2026
Perhaps most patients in that Baltimore, MD study take their medications just fine… what about those at high risk for nonadherence? Putting on a patch once a week (perhaps supervised during a home visit by a health worker) could be a real improvement over twice-daily pills for some PLH whom I have encountered in a developing country setting. It could certainly be easier for those with a variable sleep or work schedule. I think it would be a simpler option for me if I were on ART.
Hi Amy,
Agree it might be handy … for those who agree to do it!
I also think that Baltimore study is pretty representative of a very challenging group of patients — here’s my review of it:
http://cid.oxfordjournals.org/content/53/6/605.full
My rough estimate is that around 10-20% of HIV patients don’t take their meds, but they loom very large in our minds since we spend so much time agonizing over them!
Paul